CCKBR and neoplasm: The biodistribution of radiolabeled DOTA-CCK2R derivatives using the therapeutic radionuclide Lu-177 is shown in Figure 4B. Radioactivity accumulation was exclusively observed in the tumor and kidneys 72 h after tail-vein administration.